4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid Basic information
- Product Name:
- 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid
- Synonyms:
-
- 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid
- Nilotinib EP Impurity D
- 4-Methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid
- Benzoic acid, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]-
- 4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidiny]aMino]benzoic acid
- 2-[(5-Carboxy-2-methylphenyl)amino]-4-(pyridin-3-yl)pyrimidine, 3-{2-[(5-Carboxy-2-methylphenyl)amino]pyrimidin-4-yl}pyridine
- Nilotinib Intemediate 2
- 4-Methyl-3-((4-(pyridin-3-yl)
- CAS:
- 641569-94-0
- MF:
- C17H14N4O2
- MW:
- 306.32
- EINECS:
- 629-968-8
- Mol File:
- 641569-94-0.mol
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid Chemical Properties
- Melting point:
- >257oC (dec.)
- Boiling point:
- 587.9±60.0 °C(Predicted)
- Density
- 1.336
- storage temp.
- under inert gas (nitrogen or Argon) at 2–8 °C
- solubility
- DMSO (Slightly), Methanol (Slightly, Heated)
- pka
- 4.35±0.10(Predicted)
- form
- Solid
- color
- Pale Beige
- Stability:
- Hygroscopic
- InChI
- InChI=1S/C17H14N4O2/c1-11-4-5-12(16(22)23)9-15(11)21-17-19-8-6-14(20-17)13-3-2-7-18-10-13/h2-10H,1H3,(H,22,23)(H,19,20,21)
- InChIKey
- LDLZPHLSVKGFSC-UHFFFAOYSA-N
- SMILES
- C(O)(=O)C1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1
- CAS DataBase Reference
- 641569-94-0(CAS DataBase Reference)
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid Usage And Synthesis
Uses
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid is used in the preparation of (pyridinyl)-N-[(triazolyl)phenyl]pyrimidinamine derivatives and (pyridinyl)-N-[oxadiazolyl)phenyl]pyrimidinamine derivatives, and can be used in the detection of their activity as antileukemia agents (neoplastic stem cell leukemia). 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid is also a Nilotinib (N465300) intermediate, which might be useful in treatment of chronic myelogenous leukemia.
Synthesis
3- [(Aminoiminomethyl)amino] -4-methyl-benzoic acid methyl ester mononitrate (10 g),3-(Dimethylamino)-1-(pyridine-3-yl)prop-2-en-1-one (7.3 g), sodium hydroxide (1.7 g) was added to 1-butanol (100 mL) in a round bottom flask under nitrogen atmosphere. The reaction mass was heated to reflux temperature and stirred for 12 hours. Then the reaction mass was cooled to 25-35°C, and iN sodium hydroxide solution (1.5 g in 37 mL of DM water) was added to it throughout 20 mm. The reaction mass was heated to reflux temperature (120-125°C) and then cooled to 25-35°C. Hydrochloric acid was added to the reaction mass at 25-35°C and stirred for an hour. The material formed was filtered, washed with DM water and then dried under vacuum at 50-55°C to provide 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid (8.7 g).
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acidSupplier
- Tel
- 0514-80939770 13773367191
- yzqyyykj@163.com
- Tel
- 021-68900963 15618693615
- sales@jinghaopharma.com
- Tel
- 400-8675577 19945755304
- sales@chemany.com
- Tel
- 023-023-63134718 13983849334
- 1501533472@qq.com
- Tel
- 023-68509220
- sales1@biolandpharm.com
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid(641569-94-0)Related Product Information
- 4-Dimethylaminobenzoic acid
- Methyl acrylate
- 4-Aminobenzoic acid
- Glycine
- Methyl cellulose
- Bensulfuron methyl
- METSULFURON METHYL
- Methylparaben
- Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]-
- Methyl
- 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline
- 4-(pyridine-2-yl) pyrimidin-2-amine
- Nilotinib N-Oxide
- 3-Amino-5-bromobenzotrifluoride
- 3-Iodo-4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]benzamide
- 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide
- Nilotinib impurity 3
- Nilotinib Impurity 28